RCC: better QoL with front-line atezolizumab+bevacizumab

  • Atkins MB & al.
  • Clin Cancer Res
  • 3 mars 2020

  • Par Deepa Koli
  • Résumés d'articles
L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte. L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte.

Takeaway

  • Front-line atezolizumab+bevacizumab was associated with milder symptoms, better health-related QoL (HRQOL), less bother from treatment adverse effects, less functional impairment, and a delay in meaningful deterioration of daily functioning in patients with metastatic renal cell carcinoma (RCC) vs sunitinib.

Why this matters

  • Patient-reported outcomes (PROs) add to clinical benefit with this regimen and will help clinicians personalize treatment for patients.

Study design

  • PROs of phase 3 randomized IMmotion151 trial.
  • 915 treatment-naive patients with metastatic RCC were randomly assigned to either atezolizumab+bevacizumab or sunitinib.
  • Funding: F. Hoffmann-La Roche Ltd/Genentech, Inc.

Key results

  • Milder symptoms (P<.05 less symptom interference and better hrqol at most visits in the atezolizumab group through weeks.>
  • Patients receiving atezolizumab+bevacizumab reported less bother from adverse effects throughout the study (differences in proportions of patients reporting "not at all" or "a little bit": 14%-35%).
  • Patients receiving atezolizumab+bevacizumab reported significantly longer time to deterioration for:
    • Core symptom: stratified (s)HR, 0.50 (95% CI, 0.40-0.62).
    • RCC symptom: sHR, 0.45 (95% CI, 0.37-0.55).
    • HRQOL: HR, 0.68 (95% CI, 0.58-0.81).

Limitations

  • Reasons for noncompletion of PROs form not captured.